Daxor Corporation Expands BVA Program
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, has announced the expansion of its blood volume analysis (BVA) technology with the acquisition of a new BVA analyzer. This development not only boosts revenue but also paves the way for anticipated sales growth for the remainder of the year.
Community Hospital's Acquisition for Enhanced Care
A rural community hospital with 339 beds has recently acquired a BVA analyzer to enhance outpatient care for heart failure patients. This acquisition is vital for improving patient outcomes, particularly in areas where access to specialized medical care is often limited. The urgency for effective heart failure management is highlighted by concerning statistics that show high rates of heart disease in the region.
Importance of Outpatient Heart Failure Care
Outpatient heart failure care plays a crucial role in proactive management, early intervention, and ongoing monitoring. These factors are essential for preventing hospitalizations and improving patient outcomes, all while helping to lower healthcare costs. Michael Feldschuh, Daxor’s CEO and President, underscores the importance of the BVA diagnostic tool, which delivers 98% accurate actionable data to assist in fluid management decisions. This capability allows healthcare providers to tailor care plans to individual patients, enabling them to manage their chronic conditions effectively and maintain a good quality of life.
About Daxor Corporation
Daxor Corporation is dedicated to innovating blood volume measurement technology, particularly through blood volume testing. The company has developed and markets the BVA-100™ (Blood Volume Analyzer), which is the only FDA-cleared diagnostic blood test that accurately measures blood volume status and composition. To date, over 65,000 tests have been conducted at leading hospital centers across the United States. These tests have significantly improved hospital performance metrics across various surgical and medical conditions, leading to a notable reduction in mortality and readmission rates for heart failure and critical care patients.
Ongoing Trials and Future Directions
Daxor is currently involved in multiple trials focused on heart failure treatment, with support from the National Institutes of Health (NIH). Furthermore, the company has a contract to develop analyzers aimed at enhancing combat casualty care in collaboration with the U.S. Department of Defense. This dedication to advancing healthcare through effective fluid management establishes Daxor as a key player in clinical environments.
Contact Information
For more information, individuals can contact Bret Shapiro, Sr. Managing Partner at CORE IR, by phone at 1-516-222-2560 or via email at brets@coreir.com.
Frequently Asked Questions
What is the main purpose of the BVA program launched by Daxor Corporation?
The BVA program is designed to enhance outpatient heart failure care through advanced blood volume analysis technology, ultimately improving patient outcomes.
What technology does Daxor's BVA analyzer use?
The BVA analyzer employs innovative technology that provides 98% accurate data to guide fluid management decisions for patients with heart failure.
How has Daxor performed in terms of testing?
Daxor has successfully conducted over 65,000 tests at various hospital centers, contributing to improved patient care and lower readmission rates.
What is the future direction of Daxor Corporation?
Daxor is actively participating in trials for heart failure treatments and collaborates with the NIH, while also developing solutions for military healthcare applications.
Who can be contacted for more information about Daxor Corporation?
For inquiries, individuals can reach out to Bret Shapiro at CORE IR, who serves as the Investor Relations contact for Daxor Corporation.
